An earlier study has shown that the pharmacological inhibition of KDM1A reduces tumor growth and reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia (AML) [32]. The gene discussed is KDM1A; the disease is neoplasm.